Hexvix® improves bladder cancer free survival - data to be presented at the EAU congress

Photocure and Ipsen to co-sponsor two symposia on bladder cancer management. Data on impact of Hexvix® on long term recurrence rates to be prestented at European Association of Urology (EAU) Congress, Paris

Oslo, Norway, February 24, 2012. Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announced today that data will be presented on Hexvix at the 27th Annual European Association of Urology (EAU) Congress in Paris on 27th February 2012. Hexvix is Photocure's flagship product to aid in diagnosing bladder cancer. Photocure will also co-sponsor two symposiums with Ipsen, its strategic partner in the commercialisation of Hexvix worldwide.
 
The data on Hexvix, from a long term follow-up study in 551 patients, demonstrates that Hexvix cystoscopy significantly improves bladder cancer recurrence free survival. Professor Maximillian Burger (Caritas St. Josef Medical Centre, Regensberg, Germany) will be presenting this data during a poster session on Monday 27 February from 14.00 to 15.30.
 
The EAU Congress is Europe's largest urology event, and provides the opportunity to hear first hand from the world's leading experts on findings and insights, as well as current trends that impact the treatment of urological diseases.
 
Photocure will also co-sponsor two symposiums with Ipsen:
Non muscle invasive bladder cancer management in 2012. From recommendations to real life clinical practice. The symposium will be chaired by Professor Didier Jacqmin (Hôpitaux Universitaires de Strasbourg, France) with Professor Fred Witjes (Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands), Professor Bernard Malavaud (Hospital Rangueil, Toulouse,France), and Ass. Professor Maximillian Burger (Caritas St. Josef Medical Centre, Regensberg, Germany)
The symposium will provide a review of the latest data from two important clinical trials and will evaluate the role of Hexvix in the management of patients with bladder cancer in real life setting, and its impact on the longer term follow up of patients. This will take place on Sunday 26 February 2012, from 17:30 to 19:00 in room 251, Level 2.
 
Optimising care for bladder cancer patient. This will take place at the EAUN (European Association of Urology Nurses) on Saturday 25 February 2012, from 13:15 to 14:15 in room Havane, Level 3.  The symposium will be chaired by Francoise Charnay-Sonnek (Hòspitaux Universitaires de Strasbourg, Strasbourg, France) with Kathryn Chatterton (Guys & St Thomas's, London, UK), Colin Bruce (Barnet Hospital, Barnet, UK) and Rikke Knudsen (Skejby Hospital, Aarhus, Denmark).
 
The symposium will provide the patient perspective of dealing with bladder cancer and the role of the nurses in optimizing patient care.
 
Kjetil Hestdal, President and Chief Executive Officer of Photocure, commented: "The EAU conference is renowned for attracting leading experts to present their latest findings. We are delighted that the organisers have accepted the data on Hexvix for presentation at the meeting.  This poster, along with the symposia, will provide valuable information on the use of Hexvix in real life settings and its impact on reducing the recurrence of bladder cancer."
 
For further information, please contact:

Photocure
President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email: kh@photocure.no
M: Communications
Mary Clark, Amber Bielecka, Hollie Vile
Tel: +44 207920 2361, Email: photocure@mcomgroup.com
 
About Photocure ASA
Photocure ASA is a worldwide leader in photodynamic technology. Listed on the Oslo Stock Exchange (OSE: PHO), Photocure is focused on photodynamic technologies in dermatology and cancer. The company strives to solve unmet needs by developing new and innovative solutions based on its patented Photocure Technology(TM). Photocure markets and sells its own products in selected markets and has developed strong partnerships with leading pharmaceutical companies on a regional and global basis. Photocure's bladder cancer diagnostic product, Cysview/Hexvix is approved in Europe and the US. In addition, the company markets Allumera®, a photodynamic cosmetic in the US. Setting new standards for diagnosis and treatment of several different conditions, Photocure Technology(TM) is continuously being tested for new products and applications in cancer and dermatology.
Visonac®, Allumera®, Photocure® and Cysview®/Hexvix® are registered trademarks of Photocure ASA. For more information about Photocure, visit www.photocure.com.
This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)